SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.72+8.0%3:22 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (7250)10/28/2002 9:24:15 AM
From: Biomaven  Read Replies (1) of 52153
 
Thanks, Miljenko - I hadn't seen that abstract. Those GI and liver side effects would likely be enough to kill the drug, and they certainly were not mentioned in the VRTX presentation I saw in June.

On efficacy, note that there is apparently a significant difference in the patient populations that you now see for RA trials given that the recent patients are likely to have either milder disease or to be TNF inhibitor-refractory. So it's hard to compare with the Enbrel/Remicade trials.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News